Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

RL Milne; EL Goode; M Garca-Closas; FJ Couch; G Severi; R Hein; Z Fredericksen; N Malats; MP Zamora; JIA Perez; J Benitez; T Dork; P Schurmann; JH Karstens; P Hillemanns; A Cox; IW Brock; G Elliot; SS Cross; S Seal; C Turnbull; A Renwick; N Rahman; CY Shen; JC Yu; CS Huang; MF Hou; BG Nordestgaard; SE Bojesen; C Lanng; GG Alnaes; V Kristensen; AL Borrensen-Dale; JL Hopper; GS Dite; C Apicella; MC Southey; D Lambrechts; BT Yesilyurt; G Floris; K Leunen; S Sangrajrang; V Gaborieau; P Brennan; J Mckay; J Chang-Claude; S Wang-Gohrke; P Radice; P Peterlongo; S Manoukian; M Barile; GG Giles; L Baglietto; EM John; A Miron; SJ Chanock; J Lissowska; ME Sherman; JD Figueroa; NV Bogdanova; NN Antonenkova; IV Zalutsky; YI Rogov; PA Fasching; CM Bayer; AB Ekici; MW Beckmann; H Brenner; H Muller; V Arndt; C Stegmaier; IL Andrulis; JA Knight; G Glendon; AM Mulligan; A Mannermaa; V Kataja; VM Kosma; JM Hartikainen; A Meindl; J Heil; CR Bartram; RK Schmutzler; GD Thomas; RN Hoover; O Fletcher; LJ Gibson; ID Silva; J Peto; S Nickels; D Flesch-Janys; H Anton-Culver; A Ziogas; E Sawyer; I Tomlinson; M Kerin; N Miller; Marjanka K Schmidt; A Broeks; LJ (Laura) van 't Veer; RAEM Tollenaar; PDP Pharoah; AM Dunning; KA Pooley; F Marme; A Schneeweiss; C Sohn; B Burwinkel; A Jakubowska; J Lubinski; K Jaworska; K Durda; D Kang; KY Yoo; DY Noh; SH Ahn; DJ Hunter; SE Hankinson; P Kraft; S Lindstrom; XQ Chen; J Beesley; U Hamann; V Harth; C Justenhoven; R Winqvist; K Pylkas; A Jukkola-Vuorinen; M Grip; M Hooning; Antoinette Hollestelle; Rogier Oldenburg; Madeleine Tilanus - Linthorst; E Khusnutdinova; M Bermisheva; D Prokofieva; A Farahtdinova; JE Olson; XS Wang; MK Humphreys; Q (Qing) Wang; G Chenevix-Trench; DF Easton

doi:10.1158/1055-9965.EPI-11-0569

Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

RL Milne, EL Goode, M Garca-Closas, FJ Couch, G Severi, R Hein, Z Fredericksen, N Malats, MP Zamora, JIA Perez, J Benitez, T Dork, P Schurmann, JH Karstens, P Hillemanns, A Cox, IW Brock, G Elliot, SS Cross, S SealC Turnbull, A Renwick, N Rahman, CY Shen, JC Yu, CS Huang, MF Hou, BG Nordestgaard, SE Bojesen, C Lanng, GG Alnaes, V Kristensen, AL Borrensen-Dale, JL Hopper, GS Dite, C Apicella, MC Southey, D Lambrechts, BT Yesilyurt, G Floris, K Leunen, S Sangrajrang, V Gaborieau, P Brennan, J Mckay, J Chang-Claude, S Wang-Gohrke, P Radice, P Peterlongo, S Manoukian, M Barile, GG Giles, L Baglietto, EM John, A Miron, SJ Chanock, J Lissowska, ME Sherman, JD Figueroa, NV Bogdanova, NN Antonenkova, IV Zalutsky, YI Rogov, PA Fasching, CM Bayer, AB Ekici, MW Beckmann, H Brenner, H Muller, V Arndt, C Stegmaier, IL Andrulis, JA Knight, G Glendon, AM Mulligan, A Mannermaa, V Kataja, VM Kosma, JM Hartikainen, A Meindl, J Heil, CR Bartram, RK Schmutzler, GD Thomas, RN Hoover, O Fletcher, LJ Gibson, ID Silva, J Peto, S Nickels, D Flesch-Janys, H Anton-Culver, A Ziogas, E Sawyer, I Tomlinson, M Kerin, N Miller, Marjanka K Schmidt, A Broeks, LJ (Laura) van 't Veer, RAEM Tollenaar, PDP Pharoah, AM Dunning, KA Pooley, F Marme, A Schneeweiss, C Sohn, B Burwinkel, A Jakubowska, J Lubinski, K Jaworska, K Durda, D Kang, KY Yoo, DY Noh, SH Ahn, DJ Hunter, SE Hankinson, P Kraft, S Lindstrom, XQ Chen, J Beesley, U Hamann, V Harth, C Justenhoven, R Winqvist, K Pylkas, A Jukkola-Vuorinen, M Grip, M Hooning, Antoinette Hollestelle, Rogier Oldenburg, Madeleine Tilanus - Linthorst, E Khusnutdinova, M Bermisheva, D Prokofieva, A Farahtdinova, JE Olson, XS Wang, MK Humphreys, Q (Qing) Wang, G Chenevix-Trench, DF Easton

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

Abstract

Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 x 10(-18)) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR 1.07, 95% CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 x 10(-18) vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; P(heterogeneity) 2 x 10(-7)); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; Ptrend 5 x 10(-7)]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222-31. (C) 2011 AACR.

Original language	Undefined/Unknown
Pages (from-to)	2222-2231
Number of pages	10
Journal	Cancer Epidemiology Biomarkers & Prevention
Volume	20
Issue number	10
DOIs	https://doi.org/10.1158/1055-9965.EPI-11-0569
Publication status	Published - 2011

Research programs

EMC MM-03-47-11

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1055-9965.EPI-11-0569

http://hdl.handle.net/1765/60699

Cite this

Milne, RL., Goode, EL., Garca-Closas, M., Couch, FJ., Severi, G., Hein, R., Fredericksen, Z., Malats, N., Zamora, MP., Perez, JIA., Benitez, J., Dork, T., Schurmann, P., Karstens, JH., Hillemanns, P., Cox, A., Brock, IW., Elliot, G., Cross, SS., ... Easton, DF. (2011). Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers & Prevention, 20(10), 2222-2231. https://doi.org/10.1158/1055-9965.EPI-11-0569

@article{ca94aeeb05aa4a37bf05fb7eecdb6bf9,

title = "Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer",

abstract = "Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 x 10(-18)) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR 1.07, 95% CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 x 10(-18) vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; P(heterogeneity) 2 x 10(-7)); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; Ptrend 5 x 10(-7)]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222-31. (C) 2011 AACR.",

author = "RL Milne and EL Goode and M Garca-Closas and FJ Couch and G Severi and R Hein and Z Fredericksen and N Malats and MP Zamora and JIA Perez and J Benitez and T Dork and P Schurmann and JH Karstens and P Hillemanns and A Cox and IW Brock and G Elliot and SS Cross and S Seal and C Turnbull and A Renwick and N Rahman and CY Shen and JC Yu and CS Huang and MF Hou and BG Nordestgaard and SE Bojesen and C Lanng and GG Alnaes and V Kristensen and AL Borrensen-Dale and JL Hopper and GS Dite and C Apicella and MC Southey and D Lambrechts and BT Yesilyurt and G Floris and K Leunen and S Sangrajrang and V Gaborieau and P Brennan and J Mckay and J Chang-Claude and S Wang-Gohrke and P Radice and P Peterlongo and S Manoukian and M Barile and GG Giles and L Baglietto and EM John and A Miron and SJ Chanock and J Lissowska and ME Sherman and JD Figueroa and NV Bogdanova and NN Antonenkova and IV Zalutsky and YI Rogov and PA Fasching and CM Bayer and AB Ekici and MW Beckmann and H Brenner and H Muller and V Arndt and C Stegmaier and IL Andrulis and JA Knight and G Glendon and AM Mulligan and A Mannermaa and V Kataja and VM Kosma and JM Hartikainen and A Meindl and J Heil and CR Bartram and RK Schmutzler and GD Thomas and RN Hoover and O Fletcher and LJ Gibson and ID Silva and J Peto and S Nickels and D Flesch-Janys and H Anton-Culver and A Ziogas and E Sawyer and I Tomlinson and M Kerin and N Miller and Schmidt, {Marjanka K} and A Broeks and {van 't Veer}, {LJ (Laura)} and RAEM Tollenaar and PDP Pharoah and AM Dunning and KA Pooley and F Marme and A Schneeweiss and C Sohn and B Burwinkel and A Jakubowska and J Lubinski and K Jaworska and K Durda and D Kang and KY Yoo and DY Noh and SH Ahn and DJ Hunter and SE Hankinson and P Kraft and S Lindstrom and XQ Chen and J Beesley and U Hamann and V Harth and C Justenhoven and R Winqvist and K Pylkas and A Jukkola-Vuorinen and M Grip and M Hooning and Antoinette Hollestelle and Rogier Oldenburg and {Tilanus - Linthorst}, Madeleine and E Khusnutdinova and M Bermisheva and D Prokofieva and A Farahtdinova and JE Olson and XS Wang and MK Humphreys and Wang, {Q (Qing)} and G Chenevix-Trench and DF Easton",

year = "2011",

doi = "10.1158/1055-9965.EPI-11-0569",

language = "Undefined/Unknown",

volume = "20",

pages = "2222--2231",

journal = "Cancer Epidemiology Biomarkers & Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

Milne, RL, Goode, EL, Garca-Closas, M, Couch, FJ, Severi, G, Hein, R, Fredericksen, Z, Malats, N, Zamora, MP, Perez, JIA, Benitez, J, Dork, T, Schurmann, P, Karstens, JH, Hillemanns, P, Cox, A, Brock, IW, Elliot, G, Cross, SS, Seal, S, Turnbull, C, Renwick, A, Rahman, N, Shen, CY, Yu, JC, Huang, CS, Hou, MF, Nordestgaard, BG, Bojesen, SE, Lanng, C, Alnaes, GG, Kristensen, V, Borrensen-Dale, AL, Hopper, JL, Dite, GS, Apicella, C, Southey, MC, Lambrechts, D, Yesilyurt, BT, Floris, G, Leunen, K, Sangrajrang, S, Gaborieau, V, Brennan, P, Mckay, J, Chang-Claude, J, Wang-Gohrke, S, Radice, P, Peterlongo, P, Manoukian, S, Barile, M, Giles, GG, Baglietto, L, John, EM, Miron, A, Chanock, SJ, Lissowska, J, Sherman, ME, Figueroa, JD, Bogdanova, NV, Antonenkova, NN, Zalutsky, IV, Rogov, YI, Fasching, PA, Bayer, CM, Ekici, AB, Beckmann, MW, Brenner, H, Muller, H, Arndt, V, Stegmaier, C, Andrulis, IL, Knight, JA, Glendon, G, Mulligan, AM, Mannermaa, A, Kataja, V, Kosma, VM, Hartikainen, JM, Meindl, A, Heil, J, Bartram, CR, Schmutzler, RK, Thomas, GD, Hoover, RN, Fletcher, O, Gibson, LJ, Silva, ID, Peto, J, Nickels, S, Flesch-Janys, D, Anton-Culver, H, Ziogas, A, Sawyer, E, Tomlinson, I, Kerin, M, Miller, N, Schmidt, MK, Broeks, A, van 't Veer, LJ, Tollenaar, RAEM, Pharoah, PDP, Dunning, AM, Pooley, KA, Marme, F, Schneeweiss, A, Sohn, C, Burwinkel, B, Jakubowska, A, Lubinski, J, Jaworska, K, Durda, K, Kang, D, Yoo, KY, Noh, DY, Ahn, SH, Hunter, DJ, Hankinson, SE, Kraft, P, Lindstrom, S, Chen, XQ, Beesley, J, Hamann, U, Harth, V, Justenhoven, C, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Grip, M, Hooning, M, Hollestelle, A, Oldenburg, R , Tilanus - Linthorst, M, Khusnutdinova, E, Bermisheva, M, Prokofieva, D, Farahtdinova, A, Olson, JE, Wang, XS, Humphreys, MK, Wang, Q, Chenevix-Trench, G & Easton, DF 2011, 'Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer', Cancer Epidemiology Biomarkers & Prevention, vol. 20, no. 10, pp. 2222-2231. https://doi.org/10.1158/1055-9965.EPI-11-0569

TY - JOUR

T1 - Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

AU - Milne, RL

AU - Goode, EL

AU - Garca-Closas, M

AU - Couch, FJ

AU - Severi, G

AU - Hein, R

AU - Fredericksen, Z

AU - Malats, N

AU - Zamora, MP

AU - Perez, JIA

AU - Benitez, J

AU - Dork, T

AU - Schurmann, P

AU - Karstens, JH

AU - Hillemanns, P

AU - Cox, A

AU - Brock, IW

AU - Elliot, G

AU - Cross, SS

AU - Seal, S

AU - Turnbull, C

AU - Renwick, A

AU - Rahman, N

AU - Shen, CY

AU - Yu, JC

AU - Huang, CS

AU - Hou, MF

AU - Nordestgaard, BG

AU - Bojesen, SE

AU - Lanng, C

AU - Alnaes, GG

AU - Kristensen, V

AU - Borrensen-Dale, AL

AU - Hopper, JL

AU - Dite, GS

AU - Apicella, C

AU - Southey, MC

AU - Lambrechts, D

AU - Yesilyurt, BT

AU - Floris, G

AU - Leunen, K

AU - Sangrajrang, S

AU - Gaborieau, V

AU - Brennan, P

AU - Mckay, J

AU - Chang-Claude, J

AU - Wang-Gohrke, S

AU - Radice, P

AU - Peterlongo, P

AU - Manoukian, S

AU - Barile, M

AU - Giles, GG

AU - Baglietto, L

AU - John, EM

AU - Miron, A

AU - Chanock, SJ

AU - Lissowska, J

AU - Sherman, ME

AU - Figueroa, JD

AU - Bogdanova, NV

AU - Antonenkova, NN

AU - Zalutsky, IV

AU - Rogov, YI

AU - Fasching, PA

AU - Bayer, CM

AU - Ekici, AB

AU - Beckmann, MW

AU - Brenner, H

AU - Muller, H

AU - Arndt, V

AU - Stegmaier, C

AU - Andrulis, IL

AU - Knight, JA

AU - Glendon, G

AU - Mulligan, AM

AU - Mannermaa, A

AU - Kataja, V

AU - Kosma, VM

AU - Hartikainen, JM

AU - Meindl, A

AU - Heil, J

AU - Bartram, CR

AU - Schmutzler, RK

AU - Thomas, GD

AU - Hoover, RN

AU - Fletcher, O

AU - Gibson, LJ

AU - Silva, ID

AU - Peto, J

AU - Nickels, S

AU - Flesch-Janys, D

AU - Anton-Culver, H

AU - Ziogas, A

AU - Sawyer, E

AU - Tomlinson, I

AU - Kerin, M

AU - Miller, N

AU - Schmidt, Marjanka K

AU - Broeks, A

AU - van 't Veer, LJ (Laura)

AU - Tollenaar, RAEM

AU - Pharoah, PDP

AU - Dunning, AM

AU - Pooley, KA

AU - Marme, F

AU - Schneeweiss, A

AU - Sohn, C

AU - Burwinkel, B

AU - Jakubowska, A

AU - Lubinski, J

AU - Jaworska, K

AU - Durda, K

AU - Kang, D

AU - Yoo, KY

AU - Noh, DY

AU - Ahn, SH

AU - Hunter, DJ

AU - Hankinson, SE

AU - Kraft, P

AU - Lindstrom, S

AU - Chen, XQ

AU - Beesley, J

AU - Hamann, U

AU - Harth, V

AU - Justenhoven, C

AU - Winqvist, R

AU - Pylkas, K

AU - Jukkola-Vuorinen, A

AU - Grip, M

AU - Hooning, M

AU - Hollestelle, Antoinette

AU - Oldenburg, Rogier

AU - Tilanus - Linthorst, Madeleine

AU - Khusnutdinova, E

AU - Bermisheva, M

AU - Prokofieva, D

AU - Farahtdinova, A

AU - Olson, JE

AU - Wang, XS

AU - Humphreys, MK

AU - Wang, Q (Qing)

AU - Chenevix-Trench, G

AU - Easton, DF

PY - 2011

Y1 - 2011

N2 - Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 x 10(-18)) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR 1.07, 95% CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 x 10(-18) vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; P(heterogeneity) 2 x 10(-7)); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; Ptrend 5 x 10(-7)]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222-31. (C) 2011 AACR.

AB - Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 x 10(-18)) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR 1.07, 95% CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 x 10(-18) vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; P(heterogeneity) 2 x 10(-7)); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; Ptrend 5 x 10(-7)]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222-31. (C) 2011 AACR.

U2 - 10.1158/1055-9965.EPI-11-0569

DO - 10.1158/1055-9965.EPI-11-0569

M3 - Article

C2 - 21795498

SN - 1055-9965

VL - 20

SP - 2222

EP - 2231

JO - Cancer Epidemiology Biomarkers & Prevention

JF - Cancer Epidemiology Biomarkers & Prevention

IS - 10

ER -